Discovery and Functional Annotation of SIX6 Variants in Primary Open-Angle Glaucoma

Citation

Published Version
doi:10.1371/journal.pgen.1004372

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406781

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Discovery and Functional Annotation of SIX6 Variants in Primary Open-Angle Glaucoma

Megan Ulmer Carnes1,9, Yangfan P. Liu2,3, R. Rand Allingham3, Benjamin T. Whigham3, Shane Havens3, Melanie E. Garrett1, Chunyan Qiao4,5, NEIGHBORHOOD Consortium Investigators†, Nicholas Katsanis2, Janey L. Wiggs4, Louis R. Pasquale4,6, Allison Ashley-Koch1,7, Edwin C. Oh2,8,*, Michael A. Hauser1,3,7,*+

1 The Center for Human Genetics, Duke University, Durham, North Carolina, United States of America, 2 The Center for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States of America, 3 Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States of America, 4 Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States of America, 5 Beijing Tongren Hospital, Beijing Tongren Eye Center, Beijing Ophthalmology & Visual Sciences Key Laboratory, Capital Medical University, Beijing, China, 6 Channing Division of Network Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 7 Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America, 8 Department of Neurology, Duke University Medical Center, Durham, North Carolina, United States of America

Abstract

Glaucoma is a leading cause of blindness worldwide. Primary open-angle glaucoma (POAG) is the most common subtype and is a complex trait with multigenic inheritance. Genome-wide association studies have previously identified a significant association between POAG and the SIX6 locus (rs10483727, odds ratio (OR) = 1.32, p = 3.87 × 10−11). SIX6 plays a role in ocular development and has been associated with the morphology of the optic nerve. We sequenced the SIX6 coding and regulatory regions in 262 POAG cases and 256 controls and identified six nonsynonymous coding variants, including five rare and one common variant, Asn141His (rs33912345), which was associated significantly with POAG (OR = 1.27, p = 4.2 × 10−10) in the NEIGHBOR/GLAUGEN datasets. These variants were tested in an in vivo Danio rerio (zebrafish) complementation assay to evaluate ocular metrics such as eye size and optic nerve structure. Five variants, found primarily in POAG cases, were hypomorphic or null, while the sixth variant, found only in controls, was benign. One variant in the SIX6 enhancer increased expression of SIX6 and disrupted its regulation. Finally, to our knowledge for the first time, we have identified a clinical feature in POAG patients that appears to be dependent upon SIX6 genotype: patients who are homozygous for the SIX6 risk allele (His141) have a statistically thinner retinal nerve fiber layer than patients homozygous for the SIX6 non-risk allele (Asn141). Our results, in combination with previous SIX6 work, lead us to hypothesize that SIX6 risk variants disrupt the development of the neural retina, leading to a reduced number of retinal ganglion cells, thereby increasing the risk of glaucoma-associated vision loss.

Introduction

Primary open-angle glaucoma (POAG) is the most common type of glaucoma, a group of diseases that affect approximately 60 million people worldwide and is a leading cause of blindness [1]. Glaucoma is characterized by the progressive death of retinal ganglion cells, leading to optic nerve atrophy and loss of vision. POAG is a complex inherited disorder for which an increasing number of genetic associations have been described, each contributing modestly to disease burden [2,3].

A recent POAG genome-wide association study found a significant genetic association (rs10483727, odds ratio (OR) = 1.32, p = 3.87 × 10−11) at the SIX1/SIX6 locus [4]. Variants in the SIX1/SIX6 locus were first associated with quantitative optic nerve parameters in controls, including vertical cup-disc ratio (VCDR), which is used clinically to diagnose and monitor POAG progression [5,6]. Several studies have independently confirmed the association of the SIX1/SIX6 locus with both VCDR and POAG [7–9].

The human SIX family gene consists of six members (SIX1–SIX6), all of which contain two shared protein domains; a DNA binding homeobox domain and a SIX domain, which binds downstream effector molecules [10,11]. Members of this conserved gene family were originally identified through homology to the Drosophila melanogaster (Drosophila) sine oculis (so) gene, which is
required for proper eye development [10,11] and are thought to function as transcription factors, regulating key developmental steps through a complex regulatory network. During embryonic development, SIX1 is expressed broadly in multiple tissues, including the otic vesicle and the limb mesenchyme. However, expression of SIX6 is restricted to regions of the retina and the pituitary [10,12]. Drosophila with null so alleles have restricted retinal development, while morpholino knockdown of six6 in Danio rerio (zebrafish) embryos was recently shown to result in a small eye phenotype [10,13]. In humans, a large deletion on chromosome 14q22.3-q23 that includes SIX6 causes bilateral anophthalmia, the absence of both eyes, demonstrating the importance of SIX gene family members in ocular development and human disease [10,11,14–16].

In this study, we have extended the current understanding of the molecular contributions of SIX6 to POAG risk. First, we identified potential POAG risk alleles by sequencing the SIX6 gene in a case-control dataset; we found both common and rare coding changes within SIX6 in POAG cases, as well as sequence variants in the SIX6 enhancer. We then used the zebrafish system to demonstrate that these human coding variants have functional consequences in eye development. This analysis of 2–3 day old zebrafish embryos is not intended to fully recapitulate the glaucomatous phenotype; however, it provides in vivo data about the functional effects of human genetic variation on the human SIX6 protein in the context of eye development. We next used luciferase reporter assays, through which we show that a sequence variant found in the SIX6 enhancer of POAG patients may increase SIX6 expression. Finally, we demonstrate that POAG cases homozygous for the SIX6 risk allele rs33912345 have a significantly thinner retinal nerve fiber layer, suggesting a glaucomatous pathogenic mechanism driven by SIX6 dysfunction.

Results

Identification of SIX6 risk alleles in POAG cases

Sequencing of the SIX1 and SIX6 genes in Caucasian POAG cases and controls (262 cases, 256 controls) revealed 23 SNPs (Supplemental Table S1). Nine SNPs were identified in SIX1, but no nonsynonymous SNPs were present in the POAG cases. Sequencing of SIX6 yielded 14 variants including five rare nonsynonymous SNPs in POAG cases and controls, one common nonsynonymous SNP located in the homeobox of SIX6 (rs33912345, Asn141His), and five sequence variants within the SIX6 enhancer. All of these variants are conserved evolutionarily as shown by their positive Genomic Evolution Rate Profiling (GERP) scores (Table 1) [17].

Genotyping of rs33912345 in the Duke POAG case-control dataset (462 cases, 435 controls) resulted in a significant association (OR = 1.40, p = 0.0005, POAG case minor allele frequency (MAF) = 0.47, POAG control MAF = 0.39) with POAG. This SNP is in high linkage disequilibrium (r^2 = 0.95) with the intergenic SNP identified originally in POAG and VCDDR genome-wide association studies (rs10483727) [4–6,13].

As expected, meta-analysis of the imputed genotype data from the NEIGHBOR and GLAUGEN studies confirmed a significant association between POAG status and rs33912345 (OR = 1.27, p = 4.2 × 10^-10) and other linked SNPs in the region (Supplemental Table S2). Further examination of this locus showed that the association signal includes both upstream and downstream regions of the SIX6 transcript, while remaining entirely downstream of SIX1 (Supplemental Figure S1).

We next performed optical coherence tomography (OCT) to study the retinal characteristics of POAG cases possessing the SIX6 risk and non-risk variants (Table 2). OCT images were only available for POAG cases with the common SNP, rs33912345; no data were available for individuals with the rare SIX6 variants. We assessed retinal nerve fiber layer (RNFL) thickness in thirty POAG cases homozygous for the rs33912345 risk allele (C) or the non-risk allele (A) first by comparing age at disease diagnosis and age at OCT across the two genotypes, because age is known to influence retinal thickness and is thus a potential confounder. We observed no significant difference in age (p = 0.11, p = 0.14, respectively). Next, RNFL thickness was evaluated. The overall thickness (global RNFL) was reduced significantly in cases homozygous for the risk allele compared to cases with the non-risk allele (p = 0.03; mean (SD): C = 58.3 (3.2) µm, A = 67.9 (12.4) µm; Table 2), consistent with the hypothesis that SIX6 may increase POAG susceptibility via changes in the neural retina. To determine which quadrants might be driving this observation, we performed an exploratory, post-hoc comparison of RNFL thickness in the temporal, nasal, inferior, and superior regions. We found that RNFL thickness was reduced significantly in the inferior (p = 0.03) and superior (p = 0.04) quadrants, the two regions affecting directly VCDDR measurements.

In vivo functional interrogation of SIX6 missense variants

Given 1) the observed association signal pattern; 2) the lack of coding changes identified in SIX1; 3) the presence of rare missense variants and a common, associated missense SNP in SIX6; 4) retinal nerve fiber layer thickness changes observed in POAG cases homozygous for the SIX6 risk allele; and 5) the localized expression of SIX6 in ocular tissues, we concluded SIX6 is a likely candidate gene in this region. We therefore evaluated the functional relevance of SIX6 and the potential burden of common and rare alleles in this locus in POAG using an in vivo zebrafish complementation assay.

First, we performed a reciprocal BLAST analysis; we identified two orthologs of SIX6 in the zebrafish genome, Six6a and Six6b, both with 91% homology at the protein level (Supplemental Figure S2). Previous overexpression and loss of function studies of Six6 in Mus musculus (mouse) and Xenopus laevis (Xenopus) models reveal a role in regulating the proliferative state of retinal progenitor cells and the size of the eye [18,19]; therefore, as a first test of whether the identified SIX6 variants are pathogenic and
Table 1. SIX6 variants identified by sequencing POAG cases and controls.

<table>
<thead>
<tr>
<th>Gene Coordinates</th>
<th>SNP ID</th>
<th>MAF POAG Cases</th>
<th>MAF POAG Controls</th>
<th>Base Change</th>
<th>AA Change</th>
<th>GERP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0.002</td>
<td>0</td>
<td>C→G</td>
<td>Glu93Gln</td>
<td>5.52</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.002</td>
<td>0</td>
<td>C→A</td>
<td>Asn141His</td>
<td>5.38</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.002</td>
<td>0</td>
<td>G→A</td>
<td>Glu205Arg</td>
<td>4.14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.002</td>
<td>0</td>
<td>G→T</td>
<td>Thr212Met</td>
<td>2.36</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.002</td>
<td>0</td>
<td>T→C</td>
<td>Ser242Ile</td>
<td>5.19</td>
</tr>
</tbody>
</table>

Coordinates are based on the Hg19 reference; MAF = minor allele frequency; AA = amino acid; GERP = Genomic Evolutionary Rate Profiling.

doi:10.1371/journal.pgen.1004372.t001

Functional Annotation of SIX6 in Glaucoma

Using translation-blocking morpholinos (MOs) targeting zebrafish *six6a* and *six6b*, we injected 1–9 cell stage embryos (N = 50–150) and analyzed live embryos at 3 days post fertilization (dpf). We also tested a splice blocking MO. However, this induced nonspecific toxicity, including the accumulation of pericardial fluid that could not be rescued with the human SIX6 transcript. This is not unexpected, as SIX6 is a two exon gene—splice-blocking MOs are generally not recommended for two exon genes; the targeted transcript will not be subject to nonsense mediated decay, possibly leading to the expression of a truncated protein and potential dominant-negative effects (described by the manufacturer: http://www.gene-tools.com/node/18). For these reasons, we used translation-blocking MOs for the remainder of our experiments. Masked scoring of both *six6a* and *six6b* morphants revealed ocular phenotypes consistent with loss of function, including a reduction in eye size in more than 80% of embryos (p < 0.001, Figure 1). The specificity of the MO was tested by co-injection of 12.5 pg of the human SIX6 non-risk allele mRNA; we observed significant (p < 0.001) rescue in *six6a* but not *six6b* morphant embryos (90% vs. 10% of embryos, respectively). Together, these data indicate that Six6a is the functional ortholog of human SIX6 and prompted subsequent evaluation of SIX6 variants using the *six6a* MO.

To investigate the pathogenic potential of all SIX6 variants, we used total eye size and the rescue of the morphant phenotype as the assay’s phenotypic readout. We injected a mixture containing *six6a* MO and each of the human SIX6 alleles containing the coding variants identified via sequencing (Table 1). Subsequent to triplicate injections and masked scoring, these results were compared to the rescue condition of the human SIX6 non-risk allele. We found that five of the six variants tested were unable to fully rescue the small eye phenotype. Four of these alleles (*Glu129Lys, Asn141His, Thr212Met, and Ser242Ile*) resulted in an average eye size larger than the morpholino alone (p < 0.001), but smaller than the rescue with the non-risk allele (p < 0.001), indicating that these alleles are hypomorphic (Figure 2, Table 3). We also observed one variant (*Leu205Arg*) with an average eye size smaller than the morpholino alone (p = 0.002; mean (SD): 34,042 (5,763) μm², Leu205Arg = 31,568 (6,485) μm²; Figure 2), suggesting that it is functionally null. Finally, one allele (*Glu93Gln*) resulted in an eye size similar to the rescue with the non-risk allele (p = 0.37) and was determined to be benign. The benign allele was identified in one control individual, while the remaining hypomorphic and null alleles were identified either exclusively or primarily in POAG cases (Table 1). Injection of 12.5 pg of the human SIX6 risk mRNA into non-morphant zebrafish provided no evidence of a toxic gain of function compared to injection with the non-risk allele (data not shown).

Given the reduction of the RNFL in cases homozygous for the risk allele, we next asked whether *six6a* and the identified SIX6 variants impacted the optic nerve, an anatomical site directly relevant to human POAG, in zebrafish. Using whole mount imaging of acetylated-tubulin expression in 2-dpf embryos injected with a control and *six6a* morpholino, we evaluated volumetric regions of interest (ROI) along the optic nerve (Supplemental Figure S3). Masked scoring of embryos revealed an approximately 3-fold reduction (p < 0.001) in the volume of the optic nerve upon depletion of *six6a* (Figure 3 A–B). This was specific for the optic nerve as the volume of other axonal tracts in the brain were unaffected by *six6a* depletion (Figure 3A). Specificity of the
volumetric measurements was demonstrated upon full rescue of the \textit{six6a} morphant phenotype by co-injection of the non-risk allele (p<0.001) or a variant that scored as a benign allele in the eye size assay (Glu93Gln; p<0.001; Figure 3B). Both Leu205Arg and Asn141His variants performed as hypomorphic alleles (p<0.01), revealing concordance of our optic nerve assay with the OCT imaging findings in patients.

**In vitro functional interrogation of \textit{SIX6} enhancer variants**

We hypothesized that POAG risk may be mediated not only by deficits in \textit{SIX6} protein function, but also by the level of \textit{SIX6} gene expression. To test this, we sequenced the \textit{SIX6} retinal specific enhancer element in 262 POAG cases and 256 POAG controls; we identified five variants (Chr14:60974363_C, Chr14:60974373_T, Chr14:60974378_T, Chr14:60974400_A, Chr14:60974449_G) (Table 1), and tested their effect on expression using an \textit{in vitro} luciferase assay. We found that one of these variants (Chr14:60974449_G) resulted in a significant increase in expression compared to the reference enhancer (Figure 4). Activation of the \textit{SIX6} enhancer requires two cofactors, NeuroD and E47 (Supplemental Figure S4) [12]. Overexpression was observed with the Chr14:60974449_G variant even in the absence of these cofactors (Supplemental Figure S5), suggesting variants within the enhancer region may result in dysregulated protein expression.

**Discussion**

The \textit{SIX1}/\textit{SIX6} locus has been shown to be associated significantly with POAG in several independent studies; however, the causal variant(s) driving this association have remained unknown [4,6–9,13], as has the direction of effect of these common alleles on protein function. We have demonstrated through several lines of evidence—the tissue specificity of the \textit{SIX} gene family described in the literature; the identification of \textit{SIX6} missense variants in our POAG dataset; and the results of the \textit{in vivo} and \textit{in vitro} assays—that \textit{SIX6} is the most likely POAG susceptibility gene in this region. We identified both common and rare coding variants that alter the function of the \textit{SIX6} protein.

We also identified a novel variant within the \textit{SIX6} enhancer that appears to disrupt the regulation of \textit{SIX6} expression, suggesting both regulatory and coding variants may influence POAG susceptibility at this locus. Finally, we identified hitherto unknown clinical features in POAG patients that may be dependent upon \textit{SIX6} genotype: patients homozygous for the \textit{SIX6} risk allele have a significantly thinner retinal nerve fiber layer than patients homozygous for the \textit{SIX6} non-risk allele.

The common variant, rs33912345 (Asn141His), which we showed has significantly reduced function in an \textit{in vivo} model, was associated with POAG in our dataset and is in strong linkage disequilibrium with the originally identified GWAS SNP, rs10483727 [4]. This conserved amino acid is located within the alpha helix structure of the DNA homeobox domain of \textit{SIX6}. Interestingly, the ancestral allele (C, His) is associated with POAG risk. The allele frequency of this variant differs markedly among populations (C allele frequency: YRI (0.99), ARF (0.96), ASN (0.76), and CEU (0.42); from 1000 Genomes release 14) [20]. This locus is associated significantly with an increase in

![Table 2. OCT measurements from POAG cases homozygous for rs33912345.](https://doi.org/10.1371/journal.pgen.1004372.t002)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Allele</th>
<th>N</th>
<th>Mean (SD)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at POAG diagnosis (years)</td>
<td>A</td>
<td>18</td>
<td>63.9 (9.1)</td>
<td>0.11</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>69.7 (10.2)</td>
<td></td>
</tr>
<tr>
<td>Age at OCT measurement (years)</td>
<td>A</td>
<td>18</td>
<td>71.2 (9.7)</td>
<td>0.13</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>76.9 (10.3)</td>
<td></td>
</tr>
<tr>
<td>Nerve fiber thickness (µm): Global</td>
<td>A</td>
<td>18</td>
<td>67.9 (12.4)</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>58.3 (8.2)</td>
<td></td>
</tr>
<tr>
<td>Temporal</td>
<td>A</td>
<td>18</td>
<td>57.2 (15.2)</td>
<td>0.85</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>56.2 (12.8)</td>
<td></td>
</tr>
<tr>
<td>Nasal</td>
<td>A</td>
<td>18</td>
<td>57.4 (13.4)</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>47.9 (12.8)</td>
<td></td>
</tr>
<tr>
<td>Inferior</td>
<td>A</td>
<td>18</td>
<td>79.6 (18.7)</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>65.2 (12.6)</td>
<td></td>
</tr>
<tr>
<td>Superior</td>
<td>A</td>
<td>18</td>
<td>77.0 (22.2)</td>
<td>0.04</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>63.9 (10.8)</td>
<td></td>
</tr>
</tbody>
</table>

\(SD = \) standard deviation; \(OCT = \) optical coherence tomography.
doi:10.1371/journal.pgen.1004372.t002

![Figure 1. Morpholino knockdown of \textit{six6a}. Zebrafish were microinjected with a \textit{six6a} translation blocking morpholino. Lateral images, taken 3 days post fertilization (3 dpf), of a wild-type zebrafish (left) and a morpholino injected zebrafish (right) are shown, highlighting the small eye phenotype (dashed circle).](https://doi.org/10.1371/journal.pgen.1004372.g001)
vertical cup-disc ratio (VCDR) in population controls, indicating that it may be involved in the development of the optic nerve. VCDR is also a clinical measure used to track disease progression in POAG patients [5,6,9,13,21]. We note that African populations have larger VCDR and an increase in overall POAG prevalence [22–24] compared to CEU populations; in a recent

Figure 2. In vivo zebrafish morpholino complementation assay showing the effect of SIX6 nonsynonymous variants. Zebrafish embryos were microinjected with a translation blocking morpholino designed to target six6a. Total eye size (μm²) was measured 3 days post fertilization. Compared to the uninjected controls, morphants showed a significant reduction in eye size. Zebrafish were co-injected with the morpholino and a human SIX6 allele (Glu93Gln, Glu129Lys, Asn141His, Leu205Arg, Thr212Met, or Ser242Ile). Results of each allele were compared to the SIX6 non-risk allele (Ref). P-values are provided below the mean of each treatment.

doi:10.1371/journal.pgen.1004372.g002

Table 3. Results from the in vivo zebrafish six6a morpholino complementation assay.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N</th>
<th>Mean (SD), μm²</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uninjected Control</td>
<td>146</td>
<td>53,140 (4,536)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Translation Blocker</td>
<td>153</td>
<td>34,042 (5,763)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Human SIX6 Non-risk allele</td>
<td>177</td>
<td>49,040 (11,652)</td>
<td>Ref</td>
</tr>
<tr>
<td>Glu93Gln Variant allele</td>
<td>92</td>
<td>50,010 (5,893)</td>
<td>0.37</td>
</tr>
<tr>
<td>Glu129Lys Variant allele</td>
<td>100</td>
<td>44,719 (6,791)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Asn141His Variant allele</td>
<td>129</td>
<td>43,150 (10,660)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Leu205Arg Variant allele</td>
<td>101</td>
<td>31,568 (6,485)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Thr212Met Variant allele</td>
<td>84</td>
<td>38,278 (7,244)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ser242Ile Variant allele</td>
<td>88</td>
<td>38,420 (7,310)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

N = sample size; SD = standard deviation.
doi:10.1371/journal.pgen.1004372.t003
study, the prevalence of POAG in Ghana exceeded 17%, the highest rate observed anywhere in the world [25]. While rs33912345 is not associated with POAG risk in a West African POAG case/control dataset from Ghana, the frequency of the ancestral (risk) allele is 99% in both cases and controls [26]. We hypothesize that differences in the structure of the optic nerve and the higher risk of POAG in individuals with African ancestry may, in part, arise from the fact that essentially all individuals in this population are homozygous for the rs33912345 ancestral risk allele.

Given the association of the SIX6 locus with neural retinal measurements such as VCDR, it is reasonable to hypothesize that causal variants may function by inducing quantitative changes in cell populations in the retina. There is extensive evidence that SIX6 regulates early retinal progenitor cell proliferation during eye development [18,19,27]. Li et al. showed that Six6−/− mice display varying degrees of retinal hypoplasia that is due to a decrease in retinal ganglion cell proliferation arising from an early exit from the cell cycle during development, and results in a 20% decrease in the number of retinal ganglion cells by P35 [18]. This is consistent with functional studies of XOptx2, the Xenopus ortholog of SIX6 [19]. We have shown a reduction in eye size and in the volume of the optic nerve upon MO knockdown of zebrafish six6a, and we were able to rescue these phenotypes with co-injection of the human SIX6 non-risk allele, demonstrating that the zebrafish six6a gene is the likely functional ortholog to human SIX6. We identified five alleles that could not rescue the small eye and optic nerve phenotypes, and we observed a reduction in retinal nerve fiber layer thickness in POAG patients homozygous for the His141 SIX6 risk allele.

Taken together with previously published findings, our results suggest that risk variants in human SIX6 increase POAG susceptibility by negatively affecting retinal ganglion cell development, likely leading to a reduction in the number of retinal ganglion cells (RGCs) and, consequently, a decrease in VCDR. This hypothesis is supported by the observation that the SIX6 variants, which are associated with POAG, are also associated with smaller eye size and optic nerve volume in zebrafish.

Figure 3. Functional evaluation of SIX6 variants on the volume of the optic nerve. Representative whole mount images of acetylated-tubulin expression in the heads of zebrafish embryos injected with a control or six6a morpholino, rescued by co-injection with human non-risk SIX6 transcript or a transcript containing the Leu205Arg hypomorphic variant (A). Acetylated-tubulin staining is restricted primarily to axon tracts and can be used to visualize the optic nerve. Relative to the control morphants, volumetric regions of interest (ROI) along the optic nerve in six6a morphants were reduced significantly. Co-injection of human variants revealed a hypomorphic (Leu205Arg, Asn141His) or benign (Glu93Gln) role of the variants on the optic nerve (B). Sample size for all injection paradigms ranged from 7–9 and p-values are plotted for each comparison (*** p<0.001; ** p<0.01). No significant changes in the volume of other axonal tracts in the head (marked by an asterisk) were detected. Standard error of the mean is shown and white scale bars = 20 um.

doi:10.1371/journal.pgen.1004372.g003
retinal ganglion cells in adulthood. Given that retinal ganglion cells are lost during the normal aging process, we speculate that this rate of loss could be increased by the presence of additional POAG risk alleles or other risk factors such as increased intraocular pressure [28]. The development of glaucomatous optic neuropathy and associated visual field loss would thus be hastened by a reduction in the initial number of retinal ganglion cells that an individual possesses. Future work will test the possibility that SIX6 variants also alter the rate of RGC death in the adult.

In summary, we have identified multiple common and rare SIX6 sequence variants in POAG cases, and used in vivo and in vitro assays to demonstrate that these variants have functional consequences on SIX6 expression and protein function. While other risk factors may be required for the onset of POAG, our data suggest that attenuation of SIX6 protein function increases an individual’s susceptibility to developing the disease via changes to retinal development. Additional work is needed, possibly through the use of transgenic animal model studies, to fully understand the role of SIX6 in POAG.

Figure 4. In vitro luciferase assay results showing the effect of SIX6 enhancer variants. SIX6 enhancer alleles were tested using a dual luciferase assay and the ratio of the experimental luciferase: control luciferase was calculated (DLR ratio). All vectors were co-transfected with NeuroD and E47. In this context, the SIX6 enhancer is functioning to increase expression compared to the empty vector (pGL4.23), driven by a minimal promoter. Compared to the reference enhancer (Ref), one variant (Chr14:60974449_G) significantly increases the enhancer’s activity. doi:10.1371/journal.pgen.1004372.g004
**Materials and Methods**

**Ethics statement**
This research was approved by the Institutional Review Board of Duke University Medical Center and adheres to the tenets of the Declaration of Helsinki.

**Subjects**
Study subjects were unrelated patients from the Duke Eye Center and, after a comprehensive eye examination, were classified as either POAG cases or controls. POAG cases presented with glaucomatous optic neuropathy, defined as a cup-to-disc ratio greater than 0.7 and visual field loss in at least one eye. Patients with secondary forms of glaucoma or a history of ocular trauma were excluded from the study. POAG controls had no evidence of optic neuropathy, normal intraocular pressure (less than 22 mmHg in both eyes), and normal visual fields, assessed using standard automated perimetry.

**DNA sequencing**
Genomic DNA was extracted from patient blood samples using the PureGene chemistry following the manufacturer’s standard protocol (Genta, Minneapolis, MN). The coding portions (2 exons) of the **SIX1** and **SIX6** genes were sequenced in 518 Caucasian POAG cases and controls (262 cases, 256 controls) using a polymerase chain-reaction (PCR) containing 1× Qiagen PCR buffer (Tris·Cl, KCl, [NH4]2SO4, 15 mM MgCl2; pH 8.7); 200 μM each of dATP, dCTP, dGTP, and dTTP; 0.4 μM forward PCR primer; 0.4 μM reverse PCR primer; 3 μL of betaine, 10 ng genomic DNA; and 0.5 U HotStarTaq DNA polymerase (Qiagen, Venlo, Limburg) to a final volume of 25 μL. Primer sequences are available in Supplemental Table S3. The PCR was performed using a touchdown protocol (incremental lowering of annealing temperature) using the following thermocycler conditions: 94° C for 30 s, 65° C for 30 s, 72° C for 30 s with a 2° C decrease in the annealing temperature every two cycles until a final annealing temperature of 55° C was reached. The retinal specific **SIX6** enhancer, previously described [12], was amplified using a touchdown protocol with a final annealing temperature of 57° C. PCR products were sequencing using the BigDye chemistry on a 3730 DNA Analyzer (Applied Biosystems, Grand Island, NY).

**Genotyping and imputation**
The common missense single nucleotide polymorphism (SNP), rs33912345, was genotyped in the Duke POAG case-control dataset consisting of 482 POAG cases and 433 POAG controls using a TaqMan allelic discrimination assay according to the standard protocols from the manufacturer (Life Technologies, Grand Island, NY). For quality control purposes the following criteria were met: >95% genotyping efficiency, matching sample duplicates (two Centre d’Etude du Polymorphisme Humain samples per 96-well plate whose genotype data matched across all plates), and Hardy-Weinberg equilibrium assumptions. We tested for association of rs33912345 with POAG using an additive logistic regression model adjusted for age and sex using SAS [29]. 

**Retinal nerve fiber layer thickness analysis**
Optical coherence tomography (OCT) measurements of retinal nerve fiber layer (RNFL) by Spectrals (Heidelberg Engineering, Carlsbad, CA) spectral domain) and fundus photography were available for all patients from the Duke Eye Center. OCT images were not routinely performed in patients without ocular disease, so there was limited data available for controls. Therefore, the analysis was restricted to POAG cases homozygous for rs33912345. Thirty patients had both OCT measurements and SIX6 genotype data. RNFL thickness, age at POAG diagnosis, and the age at OCT measurement were compared between individuals homozygous for the risk or non-risk allele using a Student’s t-test. Analyses were performed in SAS [29].

**Microinjection of morpholino and mRNA**
A vector containing human SIX6 was purchased from the CGSB Human ORFeome Collection that uses the Gateway technology system (Open Biosystems and Life Technologies, Grand Island, NY). SIX6 alleles identified by sequencing (Glu93Gln, Glu129Lys, Asn141His, Leu205Arg, Thr212Met, Ser242Ile), were created using the QuiqChange II site-directed mutagenesis kit and protocols provided by the manufacturer (Agilent Technologies). SIX6 mRNA was in vitro transcribed using mMESSAGE mMACHINE SP6 Kit (Ambion, Life Technologies, Grand Island, NY). Translation blocker (TB) morpholinos against six6a (5’-CTGGAACATGGAGACTGTAATGTCT-3’) and six6b (5’-AATTGGCAACTGAAACATGAAGGCCT-3’) were purchased from Gene Tools, LLC. Morpholino (2 ng) and mRNA (12.5 pg) were mixed and a volume of 0.5 nL was microinjected into each wild-type zebrafish embryo at one- to eight-cell stage as described previously (Stuart, McMurray et al. 1988).

**Morphometric analyses of zebrafish**
Morphometric analyses of eye size were conducted on zebrafish embryos at 3 days post fertilization, using a Nikon SMZ 745T microscope. Zebrafish were anesthetized in embryo medium containing 0.2 mg/ml tricaine (Ethyl 3-aminobenzoate methane-sulfonate, Sigma, E10521). Lateral view images were captured with Nikon DS-Fil camera, and the size of eye was measured with Nikon NIS-Elements AR software. Analysis of the optic nerve was performed on 2 dpf embryos fixed in Dent’s fixative (80% Methanol and 20% DMSO) overnight and stained with acetylated-tubulin (Sigma, T7451). Heads were isolated from stained embryos and oriented with the ventral aspect facing a coverslip on microscope cover glass. Image acquisition was performed on a Zeiss 710 inverted confocal microscope and ~100 um optical sections were obtained and reconstructed. Volumetric measurements were calculated using Imaris software and 7.5 μm×7.5 μm×15 μm ROIs along the optic nerve were analyzed between each condition. ROIs were restricted to portions of the optic nerve wherein all neurite processes coalesced to form the major aspect of the nerve.
**In vitro luciferase assay**

SIX6 enhancer alleles were tested using the dual-luciferase reporter assay system (Promega, Madison, WI). An experimental construct containing a minimal promoter (pGL4.23, firefly luciferase, Promega) was used to test the functional effect of the enhancer alleles identified by sequencing (Chr14:60974363_C, Chr14:60974373_T, Chr14:60974378_T, Chr14:60974400_A, Chr14:60974449_G) in the POAG case/control dataset. The experimental constructs (pGL4.23+Enhancer) were generated using a nested PCR protocol; the XhoI and HindIII enzymes; the Quick Ligation kit (New England BioLabs, Ipswich, MA); and the QuikChange II site-directed mutagenesis kit (Agilent Technologies), following protocols provided by the manufacturers. Constructs were confirmed to be correct by sequencing. Hek293 cells were cultured according to the supplier’s suggestions (ATCC, Manassas, VA). As described by Conte et al., co-transfection with NeuroD and E47 is required for SIX6 enhancer activation [12]. Therefore, cells were co-transfected with an experimental vector (pGL4.23+Enhancer), a control vector (pGL4.74, renilla luciferase, Promega), and vectors containing NeuroD and E47 (provided by the Center for Human Disease Modeling, Duke University) using a standard calcium phosphate transfection protocol. The experiment was performed three times in triplicate and the results were analyzed using the dual luciferase reporter (DLR) ratio (firefly luciferase sum: renilla luciferase sum) normalized by the reference SIX6 enhancer included on every plate. The data were analyzed using an ANOVA, adjusted for batch, and linear contrasts were used to determine the effect of each vector. Statistical analyses were performed in SAS [29].

**Supporting Information**

**Figure S1** Plot of the association signal from the NEIGHBOR and GLAUGEN POAG meta-analysis results observed at the SIX1/SIX6 locus calculated using chromosome 14 imputed genotype data. Generated using LocusZoom (http://genome.sph.umich.edu/wiki/LocusZoom). The color indicates the r² value with the index SNP, rs10483727.

(PDF)

**Figure S2** Results from BLAST search showing homology between human SIX6 and zebrafish Six6a and Six6b. The human SIX6 protein shares 91% identity with both of the zebrafish orthologs, Six6a and Six6b. Red: conserved across all proteins; Blue: conserved across 2 proteins; Grey: not conserved.

(TIF)

**Figure S3** Volumetric analysis of the optic nerve. Confocal image of a 2 dpf zebrafish head stained with antibody to acetylated tubulin to visualize axons. (A) Regions of Interest (ROIs) 7.5 um x 7.5 um x 15 um in size along the optic nerve were selected from reconstructed 3-dimensional images using Imaris software [X-Y plane (B–C) and X-Z plane (D–E)]. Panels C and E show the reconstructed ROI from which volumetric measurements are calculated.

(TIF)

**Figure S4** In vitro luciferase assay results from the SIX6 enhancer and co-transfection with NeuroD and E47. The SIX6 enhancer alone was inactive compared to the empty vector (pGL4.23). Co-transfection of both NeuroD and E47 increased the enhancer’s activity. The highest activity level was reached with co-transfection of an equal amount of both, as previously described [12].

(PDF)

**Figure S5** In vitro luciferase assay results showing the effect of the SIX6 enhancer without co-transfection of NeuroD and E47. SIX6 enhancer alleles were tested using a dual luciferase assay and the ratio of the experimental luciferase: control luciferase was calculated (DLR ratio). In the absence of NeuroD and E47, the SIX6 enhancer is not active. However, the Chr14:60974449_G variant still shows increased enhancer activity. Coordinates are based on the Hg19 reference. P-values are provided below the mean of each vector.

(PDF)

**Table S1** Coding variants identified by sequencing SIX1 and SIX6 in 518 POAG cases and controls. Coordinates are based on the Hg19 reference.

(DOCX)

**Table S2** Top SNPs from the imputed Chromosome 14 POAG association analysis. Plink output from meta-analysis of the NEIGHBOR and GLAUGEN logistic regression results. OR = - odds ratio.

(DOCX)

**Table S3** Primer sequences used in this study.

(DOCX)

**Acknowledgments**

Members of NEIGHBORHOOD Consortium Investigators:

Allingham, R. Rand (Department of Ophthalmology, Duke University School of Medicine); Brillant, Murray (Center for Human Genetics, Marshfield Clinic); Baden, Donald L. (Eye at Chapel Hill North, University of North Carolina School of Medicine); Chin, Hemin R. (National Eye Institute); Cooke Bailey, Jessica (Center for Human Genetic Research, Vanderbilt University School of Medicine); Fingert, John (Department of Ophthalmology, University of Iowa Medical School); Friedman, David S. (Dana Center for Preventive Ophthalmology, Johns Hopkins Hospital); Gaasterland, Douglas (Eye Doctors of Washington (EDOW)); Gaasterland, Terry (University of California San Diego, Scripps Genome Center); Haines, Jonathan (Center for Human Genetic Research, Vanderbilt University School of Medicine); Hauser, Michael A. (Center for Human Genetics, Duke University School of Medicine); Kang, Jae H. (Johns Hopkins Division of Medical Imaging Physics); Lee, Richard K. (Baylor College of Medicine); Mayeux, Ronald (University of Pennsylvania); McCarty, Cathy Essentia (Institute of Rural Health, Dalhousie, Nova Scotia); Morrison, Mark (University of Pittsburgh Medical School); Pasquale, Louis R. (University of California San Diego); Pericak-Vance, Margaret (Hussman Institute for Human Genetics at Miller School of Medicine); Reali, Anthony (Department of Ophthalmology, West Virginia University Eye Institute); Richards, Julia E. (University of Michigan Kellogg Eye Center); Schuman, Joel S. (Molecular Genomics Core Facilities, Duke University School of Medicine); Scott, William K. (McGowan Institute for Regenerative Medicine, University of Pittsburgh); Scott, William K. (Hussman Institute for Human Genetics at Miller School of Medicine); Singh, Kuldev (The Byers Eye Institute at Stanford, Stanford University School of Medicine); Sit, Arthur (Department of Ophthalmology, Mayo Clinic); Vollrath, Douglas (Stanford University School of Medicine); Weinreb, Robert N. (Shiley Eye Center, University of California San Diego); Wiggs, Janey L. (Massachusetts Eye and Ear, Harvard Medical School); Wollstein, Gadi (University of Pittsburgh School of Medicine); Wiggs, Janey L. (University of Pittsburgh School of Medicine); Zhang, Kang (Shiley Eye Center, University of California San Diego).

A list of the NEIGHBORHOOD investigators can be found at http://glaucomagenetics.org/members (accessed March 18, 2013).
Author Contributions
Conceived and designed the experiments: MUC YPL RRA BTW AAK ECO MAH. Performed the experiments: MUC YPL BTW SH CQ.

References